C4 Therapeutics director granted 62,000 stock options

C4 Therapeutics, Inc. director Steven L. Hoerter received a grant of stock options covering 62,000 shares of Common Stock.

Rhea-AI Filing Summary

C4 Therapeutics, Inc. director Steven L. Hoerter received a grant of stock options covering 62,000 shares of Common Stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.

According to the footnote, the entire option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, assuming he continues to serve on the Board through that date. After this grant, he holds 62,000 options directly.

Insider Trade Summary

Grant/Award: 62,000 shares

Grant/Award 1 txn

Insider Hoerter Steven L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Key Figures

Options granted: 62,000 options Exercise price: $4.25 per share Expiration date: June 23, 2036 +2 more

5 metrics

Options granted 62,000 options Stock Option (Right to Buy) grant to director on June 24, 2026

Exercise price $4.25 per share Exercise price for the 62,000 stock options

Expiration date June 23, 2036 Option expiration for the granted stock options

Underlying shares 62,000 shares Common Stock underlying the granted options

Holdings after grant 62,000 options Total derivative holdings following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Common Stock, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.2500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest and become exercisable financial

"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did C4 Therapeutics (CCCC) report in this Form 4 for Steven L. Hoerter?

C4 Therapeutics reported a stock option grant to director Steven L. Hoerter. He received options for 62,000 shares of Common Stock as a compensation award, recorded as an acquisition rather than an open-market purchase, with specific vesting and expiration terms.

How many C4 Therapeutics (CCCC) shares are covered by Steven Hoerter’s new options?

The new stock option grant covers 62,000 shares of Common Stock. These options give him the right to buy 62,000 shares at a preset exercise price, once the options have vested and become exercisable under the stated terms.

What is the exercise price on Steven Hoerter’s C4 Therapeutics (CCCC) stock options?

The exercise price on the options is $4.25 per share. This means that, once vested, he can purchase C4 Therapeutics Common Stock at $4.25 per share until the options reach their stated expiration date.

When do Steven Hoerter’s C4 Therapeutics (CCCC) options vest and become exercisable?

The options vest in full on the earlier of June 24, 2027 or the next annual stockholder meeting. Vesting is conditional on his continued service as a member of the Board through that date, according to the disclosed footnote.

When do Steven Hoerter’s C4 Therapeutics (CCCC) stock options expire?

The stock options expire on June 23, 2036. After that expiration date, he can no longer exercise the options to purchase Common Stock, even if they were previously vested and exercisable under the grant’s terms.

Is Steven Hoerter’s C4 Therapeutics (CCCC) Form 4 transaction a market purchase of shares?

No, the transaction is a grant of stock options, not a market purchase. The Form 4 classifies it as a grant or award acquisition, with zero purchase price today and a specified $4.25 per-share exercise price for future exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 08:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoerter Steven L.

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		(1)	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)